ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023
Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Cannabinoid modulation of central amygdala population dynamics during threat investigation.Nature communications · 2026Article
- Longitudinal changes in endocannabinoids and clinical course of adolescent non-suicidal self-injury.Translational psychiatry · 2026Article
- Endocannabinoid response to social stress in chronic non-medical prescription opioid users.Psychopharmacology · 2026Article
- Research Review: What we have learned about the endocannabinoid system in developmental psychopathology.Journal of child psychology and psychiatry, and allied disciplines · 2025Review
- Genetic Insights into Cannabis-induced Psychosis: Role of CNR1 Gene Mutation (rs1049353) and Implications- A Cross-sectional Study.Indian journal of psychological medicine · 2025Review
- Windows of change: Revisiting temporal and molecular dynamics of memory reconsolidation and persistence.Neuroscience and biobehavioral reviews · 2025Review
- Prefrontal correlates of fear generalization during endocannabinoid depletion.The Journal of clinical investigation · 2025Article
- Article
- Molecular Anatomy of Synaptic and Extrasynaptic Neurotransmission Between Nociceptive Primary Afferents and Spinal Dorsal Horn Neurons.International journal of molecular sciences · 2025Review
- Causes and countermeasures for the increased infection and COVID-19 mortality rates in patients with schizophrenia.IBRO neuroscience reports · 2024Review
- Endocannabinoids and related lipids linked to social exclusion in individuals with chronic non-medical prescription opioid use.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- PREFRONTAL CORRELATES OF FEAR GENERALIZATION DURING ENDOCANNABINOID DEPLETION.bioRxiv : the preprint server for biology · 2024Article
- Cannabinoids and monoaminergic system: implications for learning and memory.Frontiers in neuroscience · 2024Review
- Early life stress induces decreased expression of CB1R and FAAH and epigenetic changes in the medial prefrontal cortex of male rats.Frontiers in cellular neuroscience · 2024Article
- Emerging Roles of Endocannabinoids as Key Lipid Mediators for a Successful Pregnancy.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Endocannabinoids (eCBs) are lipid neuromodulators that suppress neurotransmitter release, reduce postsynaptic excitability, activate astrocyte signaling, and control cellular respiration. Here, we describe canonical and emerging eCB signaling modes and aim to link adaptations in these signaling systems to pathological states. Adaptations in eCB signaling systems have been identified in a variety of biobehavioral and physiological process relevant to neuropsychiatric disease states including stress-related disorders, epilepsy, developmental disorders, obesity, and substance use disorders. These insights have enhanced our understanding of the pathophysiology of neurological and psychiatric disorders and are contributing to the ongoing development of eCB-targeting therapeutics. We suggest future studies aimed at illuminating how adaptations in canonical as well as emerging cellular and synaptic modes of eCB signaling contribute to disease pathophysiology or resilience could further advance these novel treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.